FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Stack Library

Circadian Reset Protocol

Sleep Optimizationintermediate
32
Share
Peptides

3

Avg Daily mcg

3,000

Level

intermediate

Added

May 16, 2026

Overview

The Circadian Reset Protocol is an intermediate-level sleep optimization stack engineered to restore disrupted circadian rhythms, deepen sleep architecture, and promote neurological recovery during rest. By combining DSIP, Selank, and Epithalon, this protocol addresses the three primary drivers of poor sleep: disrupted delta-wave signaling, elevated nighttime anxiety, and dysregulated melatonin production. DSIP (Delta Sleep-Inducing Peptide) at 200mcg daily is a neuropeptide that modulates sleep architecture by promoting slow-wave (stage 3-4) sleep without the sedative hangover of pharmaceutical sleep aids. DSIP works through the hypothalamic sleep-wake axis, normalizing sleep onset latency and increasing the proportion of restorative deep sleep. Research has shown DSIP to be particularly effective for individuals with stress-related insomnia and disrupted sleep-wake cycles from shift work or travel. Selank at 300mcg daily is an anxiolytic heptapeptide derived from the naturally occurring immunomodulatory peptide tuftsin. It reduces GABAergic anxiety and calms overactive evening cortisol without cognitive impairment or dependency. By quieting the hypervigilant nervous system that keeps many people awake at night, Selank creates the neurochemical conditions necessary for natural sleep onset. It also enhances BDNF expression, supporting memory consolidation during sleep. Epithalon at 5000mcg every other day restores pineal gland function and normalizes endogenous melatonin secretion. Rather than supplementing exogenous melatonin (which can downregulate natural production), Epithalon stimulates the pineal gland to produce melatonin at physiologically appropriate times, re-anchoring the circadian clock. Protocol Notes: DSIP and Selank are best administered 60-90 minutes before desired sleep onset. Epithalon can be taken in the morning or evening on alternating days. This stack is suited for professionals dealing with high-stress schedules, frequent travelers crossing time zones, shift workers, or anyone whose natural sleep rhythm has been disrupted. A typical cycle runs 30-60 days. Users often report vivid dreaming, easier morning waking, and significantly improved daytime energy within the first two weeks.

Dosing Protocol

200 mcg

per dose

300 mcg

per dose

Epithalon

Every other day

Read more about Epithalon →

5,000 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.